Treatment of chronic myeloid leukemia in rural Rwanda: promising early outcomes
Purpose The burden of cancer is rising in low- and middle-income countries, yet cancer treatment requires resources that are often not available in these settings. Although management of chronic myeloid leukemia (CML) has been described in low- and middle-income countries, few programs involve patie...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2016
|
| _version_ | 1826265099383341056 |
|---|---|
| author | Tapela, N Nzayisenga, I Sethi, R Bigirimana, JB Habineza, H Hategekimana, V Mantini, N Mpunga, T Shulman, LN Lehmann, L |
| author_facet | Tapela, N Nzayisenga, I Sethi, R Bigirimana, JB Habineza, H Hategekimana, V Mantini, N Mpunga, T Shulman, LN Lehmann, L |
| author_sort | Tapela, N |
| collection | OXFORD |
| description | Purpose
The burden of cancer is rising in low- and middle-income countries, yet cancer treatment requires resources that are often not available in these settings. Although management of chronic myeloid leukemia (CML) has been described in low- and middle-income countries, few programs involve patients treated in rural settings. We describe characteristics and early outcomes of patients treated for CML at rural district hospitals in Rwanda.
Methods
We conducted a retrospective review of patients with confirmed BCR-ABL–positive CML who were enrolled between July 1, 2009 and June 30, 2014. Types of data included patient demographics, diagnostic work up, treatment, clinical examination, laboratory testing, and death.
Results
Forty-three patients were included, with a maximum follow-up of 58 months. Of 31 patients who were imatinib-naïve at enrollment, 54.8% were men and the median age at diagnosis was 36.9 years (interquartile range: 29-42 years). Approximately two-thirds of patients (67.7%) were on the national public insurance scheme. The imatinib dose was reduced for 16 patients and discontinued for five. Thirty-two of the 43 patients continued to have normal blood counts at last follow-up. Four patients have died and four are lost to follow-up.
Conclusion
Our experience indicates that CML can be effectively managed in a resource-constrained rural setting, despite limited availability of on-site diagnostic resources or specialty oncology personnel. The importance of model public-private partnerships as a strategy to bring high-cost, life-saving treatment to people who do not have the ability to pay is also highlighted.
|
| first_indexed | 2024-03-06T20:18:22Z |
| format | Journal article |
| id | oxford-uuid:2cf0e797-8aaa-4017-b9a7-fc8321791d77 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:18:22Z |
| publishDate | 2016 |
| publisher | American Society of Clinical Oncology |
| record_format | dspace |
| spelling | oxford-uuid:2cf0e797-8aaa-4017-b9a7-fc8321791d772022-03-26T12:39:58ZTreatment of chronic myeloid leukemia in rural Rwanda: promising early outcomesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2cf0e797-8aaa-4017-b9a7-fc8321791d77EnglishSymplectic ElementsAmerican Society of Clinical Oncology2016Tapela, NNzayisenga, ISethi, RBigirimana, JBHabineza, HHategekimana, VMantini, NMpunga, TShulman, LNLehmann, LPurpose The burden of cancer is rising in low- and middle-income countries, yet cancer treatment requires resources that are often not available in these settings. Although management of chronic myeloid leukemia (CML) has been described in low- and middle-income countries, few programs involve patients treated in rural settings. We describe characteristics and early outcomes of patients treated for CML at rural district hospitals in Rwanda. Methods We conducted a retrospective review of patients with confirmed BCR-ABL–positive CML who were enrolled between July 1, 2009 and June 30, 2014. Types of data included patient demographics, diagnostic work up, treatment, clinical examination, laboratory testing, and death. Results Forty-three patients were included, with a maximum follow-up of 58 months. Of 31 patients who were imatinib-naïve at enrollment, 54.8% were men and the median age at diagnosis was 36.9 years (interquartile range: 29-42 years). Approximately two-thirds of patients (67.7%) were on the national public insurance scheme. The imatinib dose was reduced for 16 patients and discontinued for five. Thirty-two of the 43 patients continued to have normal blood counts at last follow-up. Four patients have died and four are lost to follow-up. Conclusion Our experience indicates that CML can be effectively managed in a resource-constrained rural setting, despite limited availability of on-site diagnostic resources or specialty oncology personnel. The importance of model public-private partnerships as a strategy to bring high-cost, life-saving treatment to people who do not have the ability to pay is also highlighted. |
| spellingShingle | Tapela, N Nzayisenga, I Sethi, R Bigirimana, JB Habineza, H Hategekimana, V Mantini, N Mpunga, T Shulman, LN Lehmann, L Treatment of chronic myeloid leukemia in rural Rwanda: promising early outcomes |
| title | Treatment of chronic myeloid leukemia in rural Rwanda: promising early outcomes |
| title_full | Treatment of chronic myeloid leukemia in rural Rwanda: promising early outcomes |
| title_fullStr | Treatment of chronic myeloid leukemia in rural Rwanda: promising early outcomes |
| title_full_unstemmed | Treatment of chronic myeloid leukemia in rural Rwanda: promising early outcomes |
| title_short | Treatment of chronic myeloid leukemia in rural Rwanda: promising early outcomes |
| title_sort | treatment of chronic myeloid leukemia in rural rwanda promising early outcomes |
| work_keys_str_mv | AT tapelan treatmentofchronicmyeloidleukemiainruralrwandapromisingearlyoutcomes AT nzayisengai treatmentofchronicmyeloidleukemiainruralrwandapromisingearlyoutcomes AT sethir treatmentofchronicmyeloidleukemiainruralrwandapromisingearlyoutcomes AT bigirimanajb treatmentofchronicmyeloidleukemiainruralrwandapromisingearlyoutcomes AT habinezah treatmentofchronicmyeloidleukemiainruralrwandapromisingearlyoutcomes AT hategekimanav treatmentofchronicmyeloidleukemiainruralrwandapromisingearlyoutcomes AT mantinin treatmentofchronicmyeloidleukemiainruralrwandapromisingearlyoutcomes AT mpungat treatmentofchronicmyeloidleukemiainruralrwandapromisingearlyoutcomes AT shulmanln treatmentofchronicmyeloidleukemiainruralrwandapromisingearlyoutcomes AT lehmannl treatmentofchronicmyeloidleukemiainruralrwandapromisingearlyoutcomes |